Abstract：
:Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over a five-year time horizon. The results are reported as net change in expenditure and consequent cost/savings in Japanese yen at the time of analysis.Results: The budget impact analysis shows that an increase in reimbursement for LAIs could lead to cumulative savings of an estimated 36.6 billion JPY over five years. These savings result from a decrease in hospitalization costs and an increased usage of LAI (assumed to be 10%). Based on the sensitivity analysis, the saving estimates are most sensitive to change in market share of generic and branded oral antipsychotics.Limitations: Historical data were used to estimate the future costs of drug and hospitalization; however, it is not the best predictor of future, hence a source of potential bias. A good level of treatment adherence with oral antipsychotics was assumed, which is generally not the case; therefore, we might have overestimated the effectiveness of oral atypical antipsychotics. Additionally, the drug cost due to reimbursement might have also been overestimated because in clinical setting, the increase of LAI use may not have reached 10% of the market share. Lastly, patients' behavior was derived from models, which may have loosely approximated the reality.Conclusions: An additional reimbursement for the use of LAI in schizophrenia patients is likely to be cost neutral/cost saving and should be considered as a policy option to improve patient outcomes and budget sustainability.
journal_name
J Med Econjournal_title
Journal of medical economicsauthors
Kasahara-Kiritani M,Chaturvedi A,Inagaki A,Wakamatsu A,Jung Wdoi
10.1080/13696998.2020.1754229subject
Has Abstractpub_date
2020-08-01 00:00:00pages
848-855issue
8eissn
1369-6998issn
1941-837Xjournal_volume
23pub_type
杂志文章abstract：:Aim: To estimate the cost-effectiveness of atezolizumab compared with docetaxel and nivolumab for the treatment of advanced non-small cell lung cancer (NSCLC), as a second-line treatment, in a French setting.Materials and methods: A three-state partitioned-survival model was developed (progression-free survival, post-...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1718156
更新日期：2020-05-01 00:00:00
abstract：OBJECTIVES:This retrospective study aims to examine the association between prescribing information (PI)-concordant oral antidiabetic drug (OAD) treatment and clinical and economic outcomes in patients with type 2 diabetes mellitus and stages 3-5 chronic kidney disease (CKD). METHODS:The study used a large, national a...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2013.775135
更新日期：2013-01-01 00:00:00
abstract：:Aims: To evaluate total costs and health consequences of a colorectal cancer (CRC) screening program with colonoscopy, fecal immunochemical tests (FIT), and expanded use of multitarget stool DNA (mt-sDNA) from the perspectives of Integrated Delivery Networks (IDNs) and payers in the United States.Materials and methods...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1730123
更新日期：2020-06-01 00:00:00
abstract：OBJECTIVE:To quantify the health economic impact of managing cow milk allergy (CMA) in South Africa, from the perspective of healthcare insurers in both the private and public sectors and parents/carers of CMA sufferers. METHODS:A decision model depicting the management of CMA in South Africa was constructed, using in...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2010.482904
更新日期：2010-01-01 00:00:00
abstract：OBJECTIVE:Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitabine versus taxanes. METHODS:Women receiving first-line chemother...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990903269673
更新日期：2009-09-01 00:00:00
abstract：OBJECTIVE:Duloxetine is indicated for treatment of major depressive disorders in the UK. While clinical trials have documented its clinical effectiveness, little is known regarding the relationship between duloxetine use and healthcare utilization in community practice. This study quantifies the impact of treatment wit...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.672941
更新日期：2012-01-01 00:00:00
abstract：OBJECTIVE:To assess the cost-effectiveness of insulin detemir compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin treatment in people with type 2 diabetes mellitus (T2DM) in Denmark, Finland, Norway, and Sweden. METHODS:Efficacy and safety data were derived from a 20-week multi-centre random...
journal_title：Journal of medical economics
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.3111/13696998.2013.768999
更新日期：2013-01-01 00:00:00
abstract：BACKGROUND:A Phase-3 study of defibrotide compared with historical controls demonstrated a 23% improvement in 100-day survival post-hematopoietic stem cell transplantation (HSCT) among patients with veno-occlusive disease with multi-organ dysfunction (VOD with MOD). AIM:To estimate the budget impact and cost-effective...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2016.1275652
更新日期：2017-05-01 00:00:00
abstract：INTRODUCTION:Triple therapy using a protease inhibitor (PI) with peginterferon and ribavirin (PR) is increasingly used in patients with chronic hepatitis C virus (HCV) infection. The most recently introduced PI, simeprevir (SMV), offers high levels of viral eradication combined with a reduced overall duration of therap...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1044457
更新日期：2015-01-01 00:00:00
abstract：OBJECTIVE:The relationship between chronic noncancer pain (CNCP) control and pain medication (analgesic) adherence has not been widely documented. The primary aim of this study was to evaluate the relationship between pain intensity and the degree of adherence to analgesic medication prescribed in pain clinics. There w...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2011.598202
更新日期：2011-01-01 00:00:00
abstract：OBJECTIVE:This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective. METHODS:An analysis was conducted from a US health plan perspective to comp...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990801959656
更新日期：2008-01-01 00:00:00
abstract：OBJECTIVE:The aim of this study was to evaluate medication adherence and persistence of patients treated with Etanercept and Adalimumab for Rheumatoid Arthritis, also giving economic evaluations on therapy costs for Received Daily Dose (RDD). MATERIALS AND METHODS:This retrospective study took into account 6 years fro...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2014.902844
更新日期：2014-05-01 00:00:00
abstract：OBJECTIVES:Atazanavir (ATV) and darunavir (DRV) are protease inhibitors approved for HIV treatment in combination with ritonavir (/r). The objectives of this study were to compare persistence (time to treatment discontinuation/modification), adherence, and healthcare costs among patients with human immunodeficiency vir...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1128942
更新日期：2016-01-01 00:00:00
abstract：OBJECTIVE:The past few decades have been marked by a bold increase in national health spending across the globe. Rather successful health reforms in leading emerging markets such as BRICS reveal a reshaping of their medical care-related expenditures. There is a scarcity of evidence explaining differences in long-term m...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1093493
更新日期：2016-01-01 00:00:00
abstract：AIMS:Percutaneous closure of a patent foramen ovale (PFO) is known to lower the risk of recurrent stroke in patients with a cryptogenic stroke. However, the economic implications of transcatheter PFO closure are less well known. From a UK payer perspective, a detailed economic appraisal of PFO closure was performed for...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2018.1548355
更新日期：2019-02-01 00:00:00
abstract：:Objectives: Aging populations are contributing to an increased volume of osteoporotic fractures. The goals of this study were to (1) develop a scorecard on epidemiological burden, policy framework, service provision, and service uptake for osteoporosis in Saudi Arabia and (2) estimate the direct costs of managing oste...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2020.1737536
更新日期：2020-07-01 00:00:00
abstract：AIMS:Hormonal imbalances can affect a woman's physical and mental condition, impacting her daily life and productivity. A mobile application, "Karada-no-kimochi", predicts the menstrual cycle based on recorded data, and provides the information regarding menstruation. This study investigates the effectiveness of the ap...
journal_title：Journal of medical economics
pub_type： 杂志文章,随机对照试验
doi：10.1080/13696998.2018.1515082
更新日期：2018-11-01 00:00:00
abstract：OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696990903347172
更新日期：2009-01-01 00:00:00
abstract：INTRODUCTION:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing ∼ 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment. OBJECTIVES:To carry out an incidence-based study in three European countries: Fra...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1032974
更新日期：2015-01-01 00:00:00
abstract：AIM:This analysis assessed the direct medical costs of newly-diagnosed, temozolomide (TMZ)-treated glioblastoma (GBM) from the perspective of a US commercial setting. MATERIALS AND METHODS:The analysis included subjects identified from the IMS PharMetrics LifeLink Plus™ claims database from January 1, 2008 to August 3...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2017.1364258
更新日期：2017-12-01 00:00:00
abstract：AIMS:To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD plus neurogenic orthostatic hypotension (PD + nOH). MATERIALS AND METHODS:MarketScan Commercial and Medicare Supplemental databases (January 1, 2009-December 31, 2013) were...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2017.1284668
更新日期：2017-05-01 00:00:00
abstract：BACKGROUND:Biologic treatments have enhanced the treatment outcomes of patients with active ankylosing spondylitis (AS). Until recently, TNF-alpha-inhibitors have been the only biologics approved for the treatment of active AS. The objective of this study was to assess the potential financial impact of the first non-TN...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2018.1551227
更新日期：2019-02-01 00:00:00
abstract：:Objective: To estimate the cost-effectiveness of utidelone plus capecitabine therapy compared to capecitabine alone in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes treatment in the Chinese context and provide a reference for the marketing of utidelone in China. Methods: A Markov...
journal_title：Journal of medical economics
pub_type： 杂志文章,随机对照试验
doi：10.1080/13696998.2019.1588125
更新日期：2019-06-01 00:00:00
abstract：OBJECTIVES:To describe the changes in resource utilization in seven European countries (Germany, Greece, Portugal, Romania, Sweden, Spain, and Turkey) and direct costs in four European countries (Germany, Spain, Sweden, and Greece) over the first 12 months of insulin treatment in patients with type 2 diabetes mellitus ...
journal_title：Journal of medical economics
pub_type： 杂志文章,多中心研究
doi：10.3111/13696998.2013.812040
更新日期：2013-08-01 00:00:00
abstract：OBJECTIVE:To compare rates of severe relapse and total direct and indirect costs over a 2-year period between US-based employees with multiple sclerosis (MS) who were adherent and non-adherent to disease-modifying drugs (DMDs). METHODS:Employees with ≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim between ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.667027
更新日期：2012-01-01 00:00:00
abstract：BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.761633
更新日期：2013-01-01 00:00:00
abstract：OBJECTIVE:To assess patient characteristics, treatment patterns, and healthcare resource utilization (HRU)/costs of individuals treated for neuroendocrine tumors (NETs) in the US. METHODS:Using a US administrative claims database, this study identified commercially-insured adults newly diagnosed with carcinoid tumors ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2014.975233
更新日期：2015-02-01 00:00:00
abstract：OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2012.690801
更新日期：2012-01-01 00:00:00
abstract：OBJECTIVE:The use of hemostatic agents has increased over time for all surgical procedures. The purpose of this study was to evaluate the newer topical absorbable hemostat products Surgicel * Fibrillar † and Surgicel SNoW ‡ (Surgicel advanced products, abbreviated as SAPs) compared to the older product Surgicel Origina...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.3111/13696998.2015.1017503
更新日期：2015-06-01 00:00:00
abstract：OBJECTIVE:The purpose of this study was to determine the cost effectiveness (from a payer's perspective) of adding clostridial collagenase ointment (CCO) to selective debridement compared with selective debridement alone (non-CCO) in the treatment of stage IV pressure ulcers among patients identified from the US Wound ...
journal_title：Journal of medical economics
pub_type： 杂志文章
doi：10.1080/13696998.2016.1252381
更新日期：2017-03-01 00:00:00
